Jim Hughes

/Jim Hughes

About Jim Hughes

This author has not yet filled in any details.
So far Jim Hughes has created 7 blog entries.

NCI Team Identifies A key Molecular Defect In SDH Patients

Jim Hughes A National Cancer Institute team led by Paul Meltzer recently published a paper in Science and Translational Medicine entitled, “Recurrent epimutation of SDHC in gastrointestinal stromal tumors.” The findings have some potential implications [...]

By |2018-09-10T09:40:53-04:00February 4th, 2015|Complementary Medicine, News|

April 2011 clinical trials update

The phase III dose escalation study intended to answer questions about Gleevec blood levels has halted recruitment after failing to meet accrual goals, having recruited only five first-line GIST patients in 14 months. Informal discussions with Novartis Pharmaceuticals, the Sarcoma Alliance for Research through Collaboration (SARC) and the trial investigators provided some insight into the reasons for the change in status.

By |2014-09-17T10:15:16-04:00April 1st, 2011|Clinical Trials, News|

More Placebo Clinical Trials Predicted for Cancer Patients

More Placebo Clinical Trials Predicted for Cancer Patients. After the controversy created by the use of a placebo in an early clinical trial for GIST patients, we hoped this issue would have gone away. Last year [...]

By |2015-03-20T11:14:24-04:00August 18th, 2006|Advocacy, Clinical Trials|

SU11248 Works, Trial Ends 7 Months Early

SU11248 is similar to Gleevec in the way it works. It is a small molecule inhibitor of the receptor tyrosine kinases PDGFRA, VEGFR, KIT and FLT3. For patients with KIT or PDGFRA mutations, the main targets of this drug are still KIT and PDGRFA. SU11248 also inhibits VEGFR. This provides an anti-angiogenic effect in addition to the primary anti-tumor effect. All tumors need new blood vessels (angiogenesis) in order for tumor growth to occur; treatments that block the growth of these new blood vessels are called “anti-angiogenesis” treatments.

By |2018-07-06T13:13:59-04:00November 29th, 2005|Clinical Trials, News, Research|

Recent Posts

Upcoming Events

  1. Symptom and Side Effect Management

    June 18 @ 12:00 PM - 1:00 PM
  2. GDOL Portland 2019

    GDOL Portland 2019

    June 22 @ 8:30 AM - 6:00 PM
  3. Life Fest 2020 New Orleans

    Life Fest New Orleans

    July 10, 2020 - July 12, 2020